乙型肝炎病毒基因型与干扰素-α2b疗效的关系

The relationship between hepatitis B virus genotypes and the efficacy of interferon -α2b therapy in patients with chronic hepatitis B

目的研究乙型肝炎病毒基因型与干扰素-α2b治疗疗效的关系。方法采用DNA测序法对222例慢性乙型肝炎患者进行HBV基因分型。其中106例接受干扰素-α2b治疗6个月,观察治疗后应答率与基因型的关系。结果在106例接受干扰素-α2b治疗的患者,C基因型患者肝组织学改变明显重于B基因型。在6个月治疗结束时,B型感染者HBVDNA阴转、HBeAg血清转换和ALT复常率分别为41.9%,38.7%和58.1%,均显著高于C型患者(P<0.05)。结论HBV基因型与肝损害程度及对干扰素-α2b的应答率有一定的关系。

Objective To study the relationship between hepatitis B virus genotypes and the efficacy of interferon-α2b therapy. Methods The HBV genotypes in 222 patients with chronic hepatitis B were detected by DNA sequencing technique. Among them , 106 patients were received interferon -α2b for 6 months. Results The hepatic histological activity index in patients with genotype C infection were more higher than in genotype B; At the end of the treatment, the response rate to interferon -α2b as respect to HBV DNA negativity, HBeAg/anti-HBe seroconversion and ALT normalization in patients with hepatitis B viral B genotype was significant higher than in genotype C （P〈0.05）. Conclusion The HBV genotype determines to some extent the efficacy of interferon-α2b in patients with chronic hepatitis B.